Yuheng Pharmaceutical's Lugua Polypeptide has been withdrawn from the Internet!

On April 14, the National Health Commission issued the "Notice on Launching Special Treatment Actions for Irrational Medical Examinations", and the one-year special treatment action for unreasonable medical examinations will be officially launched.

Eliot wrote in "The Waste Land", "April is the cruelest month.

Yuheng Pharmaceutical Lugua Polypeptide was suspended from the Internet by Zhejiang, involved in bribery of more than 800,000

On April 12, the Zhejiang Pharmaceutical Equipment Procurement Center issued the "Notice on the Evaluation Results of Medical Prices and Untrustworthy Levels in Recruitment and Procurement in Our Province (2021 Phase 1)".

The notice shows that according to the relevant facts disclosed in the Criminal Judgment of the People’s Court of Ouhai District, Wenzhou City, Zhejiang Province ("(2020) Zhejiang 0304 Xingchu No.

The above-mentioned judgment shows that since 2017, the defendant Ni Dongmin has contracted the drug promotion business in Zhejiang from pharmaceutical companies such as Harbin Yuheng Pharmaceutical Co.

After the defendant Ni Dongmin took the contract, he subcontracted the business to many medical representatives or the next subcontractor, including the defendant Lu Gang, and earned 5%-10% of the promotion fee.

From May 2017 to June 26, 2019, after defendant Lu Gang obtained the promotion fee for Lugua polypeptide injection from Harbin Yuheng Pharmaceutical Co.

In the final verdict, the defendant Ni Dongmin was guilty of false invoices and was sentenced to one year and eleven months in prison and a fine of 50,000 yuan; the defendant Lu Gang was sentenced to one year and seven years in prison for bribery of non-state personnel.

According to the data, Yuheng Pharmaceutical is a wholly-owned subsidiary of Yuheng Pharmaceutical.

It is worth noting that Yuheng Pharmaceutical was questioned by the Shenzhen Stock Exchange due to the excessively rapid growth of sales expenses from 2016 to 2018.

Sword refers to medical rebates, recruits and purchases the "bright sword" credit evaluation system

Regarding the incident, the National Medical Insurance Bureau issued a document on its official website on April 13th, stating that this is a "bright sword" of the medical price and recruitment credit evaluation system.

It is reported that Zhejiang Province has also carried out credit evaluations in accordance with procedures for other pharmaceutical companies with rebate problems, and some pharmaceutical companies have taken measures such as proactive price reductions to restore credit.

In August 2020, the National Medical Insurance Bureau launched the construction of a medical price and credit evaluation system, and pointed out prominent issues such as rebates in the medical field.

Regarding speeding up the implementation of the medical price and recruitment credit evaluation system, at the end of last year, the National Medical Insurance Bureau issued a notice again that all provincial medical insurance bureaus and centralized procurement agencies must establish a medical price and recruitment credit evaluation system before the end of 2020.

According to the requirements of the notice, since the date when the provincial medicine price and credit evaluation system for recruitment and procurement takes effect, pharmaceutical companies participating in or entrusting to participate in centralized procurement, online procurement, and filing procurement of drugs and medical consumables must submit a trustworthy commitment.

A batch of pharmaceutical companies have been fined, and the storm of "anti-corruption" in medicine strikes

On April 12, the Ministry of Finance issued an announcement on the quality inspection of accounting information for pharmaceutical companies.

According to Article 42 of the "Accounting Law of the People's Republic of China", the Ministry of Finance imposed administrative penalties on 19 pharmaceutical companies inspected by relevant regulatory bureaus of the Ministry of Finance.
Among the 19 companies, there are A-share listed pharmaceutical companies such as Hengrui Pharmaceuticals, China Resources Sanjiu, and Buchang Pharmaceuticals, as well as well-known multinational pharmaceutical companies such as Eli Lilly and Sanofi.
The penalties are mostly between 30,000 and 50,000.
(For details, see: "Announcement of audit results of pharmaceutical companies! 19 companies including Sanofi, Eli Lilly, Hengrui, and Buchang were fined")

Or because of this unfavorable news, Hengrui Pharmaceuticals, known as "Moutai in the pharmaceutical industry," the share price of Hengrui Pharmaceuticals fell all the way after the opening on April 14, falling by more than 7.
5%, setting a new low in 10 months.

The Ministry of Finance's announcement pointed out that other pharmaceutical companies will be subject to administrative punishments on the spot by the Ministry of Finance (Bureau) responsible for the inspection.
Other violations of laws and regulations found in the inspection shall be transferred to the competent authority for handling.
And on March 12, the Zhejiang Provincial Department of Finance announced the relevant administrative decision on Asia Pacific Pharmaceuticals, specifically because of the problems of Asia Pacific Pharmaceuticals reimbursing sales expenses: For example, in January 2018, the travel expenses of 19510 yuan were reimbursed, and the voucher is Large truck highway toll invoices.
In terms of promotion service fees, Asia-Pacific Pharmaceuticals and Changdian Pharmaceutical signed contracts for market research services and pharmaceutical management services.
There are inconsistencies in the research location of the same contract, the work summary is completed earlier than the contract signing date, and different contracts are in terms of meeting photos.
The same situation of height mine.
.
.

Judging from recent actions, the industry expects that the financial departments of various provinces will successively announce the penalties of some pharmaceutical companies.

On the other hand, the Central Commission for Discipline Inspection also made it clear in its 2021 tasks to rectify corruption and style issues in the medical field.
On April 10, the website of the State Supervision Commission of the Central Commission for Discipline Inspection updated a piece of news that Dai Longyong, the legal representative of Jiangxi Yongchang Pharmaceutical Co.
, Ltd.
, was suspected of committing bribery crimes.
He is currently under supervision and investigation by the Jiangxi Provincial Supervisory Commission and has been subject to lien measures; April 4 In Japan, the official website of the China Commission for Discipline Inspection pointed out in the article “Yunnan Seriously Investigates and Punishes 12 Bribery Personnel in the Medical Field” that since this year, the Yunnan Provincial Commission for Discipline Inspection has successively lied 3 batches of 12 persons suspected of bribery in the medical field.
Measures.
.
.

On April 14, the National Health Commission issued the "Notice on Launching Special Actions for Unreasonable Medical Examinations.
" In accordance with previous relevant requirements, the National Health Commission, the General Administration of Market Supervision, the National Medical Insurance Administration, the National Traditional Chinese Medicine Administration, the National Food and Drug Administration, and the Health Bureau of the Central Military Commission’s Logistics Support Department carried out a one-year special treatment action for unreasonable medical inspections.

In the quantification table for special governance of unreasonable medical inspections, the discovery and handling of violations of laws and regulations include “setting business income indicators for departments or medical staff, direct linking of business income to medical staff salaries, violation of configuration planning, unauthorized procurement and configuration of large-scale inspection equipment "For 17 items, the penalty agency is facing suspension of business for rectification, and the personnel involved are at risk of suspension of practice and revocation of practice certificates.

Under the normalization of the national procurement of pharmaceutical consumables with volume, it is expected that the marketing models of many pharmaceutical companies will change.
However, it can also be seen that due to a series of factors such as consistency evaluation, the current collections are still limited, and it is impossible to completely eliminate phenomena such as medical rebates and corruption.
Since the beginning of this year, the Central Commission for Discipline Inspection, the Ministry of Finance, the Medical Insurance Bureau, and the National Health and Medical Commission have successively been anti-corruption in medicine.
Those companies that have unusually high sales expenses, false expenses, and bribery of doctors will be the focus of attention.
The marketing and promotion of pharmaceutical products need to be more compliant, and the traditional sales model with gold is facing "disintegration"; at the same time, medical institutions, medical staff and other unreasonable behaviors are also facing the risk of being punished.
.
.
You can see that the entire pharmaceutical industry is anti-corruption The intensity is fully upgraded.